• Ascendis Pharma entered a binding term sheet with BioMarin for a global settlement and license covering YUVIWEL (navepegritide) products.
• BioMarin will grant a non-exclusive, worldwide, royalty-bearing license, preserving Ascendis’ rights to develop, manufacture, commercialize navepegritide.
• Ascendis will pay royalties on net sales of 20% in the U.S. and 18% in the EU, South Korea, Brazil through May 20, 2030.
• Both sides agreed to dismiss litigation; BioMarin will provide a covenant not to sue and waive certain regulatory rights, exclusivities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascendis Pharma A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608310700PRIMZONEFULLFEED9818268) on August 31, 2026, and is solely responsible for the information contained therein.